Is Syros Pharmaceuticals Stock a Good Investment?
Syros Pharmaceuticals Investment Advice | SYRS |
- Examine Syros Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Syros Pharmaceuticals' leadership team and their track record. Good management can help Syros Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Syros Pharmaceuticals' business and its evolving consumer preferences.
- Compare Syros Pharmaceuticals' performance and market position to its competitors. Analyze how Syros Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Syros Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Syros Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Syros Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Syros Pharmaceuticals is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Syros Pharmaceuticals Stock
Researching Syros Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 76.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 3.07. Syros Pharmaceuticals had not issued any dividends in recent years. The entity had 1:10 split on the 19th of September 2022.
To determine if Syros Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Syros Pharmaceuticals' research are outlined below:
| Syros Pharmaceuticals generated a negative expected return over the last 90 days | |
| Syros Pharmaceuticals has high historical volatility and very poor performance | |
| Syros Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Syros Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 9.94 M. Net Loss for the year was (164.57 M) with profit before overhead, payroll, taxes, and interest of 14.88 M. | |
| Syros Pharmaceuticals currently holds about 244.48 M in cash with (109.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.09, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Syros Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 76.0% of the company shares are owned by institutional investors | |
| Latest headline from ndtv.com: Kia Syros Compact SUV To Get Panoramic Sunroof- Teaser Confirms |
Syros Pharmaceuticals Quarterly Cash And Short Term Investments |
|
Syros Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Syros Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Syros Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Syros Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Syros Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-08-08 | 2023-06-30 | -1.13 | -1.3 | -0.17 | 15 | ||
2024-07-31 | 2024-06-30 | -0.77 | -0.59 | 0.18 | 23 | ||
2023-05-10 | 2023-03-31 | -1.09 | -0.85 | 0.24 | 22 | ||
2023-11-14 | 2023-09-30 | -1.14 | -1.43 | -0.29 | 25 | ||
2020-05-07 | 2020-03-31 | -4.34 | -3.9 | 0.44 | 10 | ||
2020-11-05 | 2020-09-30 | -3.84 | -4.3 | -0.46 | 11 | ||
2019-03-07 | 2018-12-31 | -4.9 | -5.4 | -0.5 | 10 | ||
2019-08-01 | 2019-06-30 | -4.16 | -4.7 | -0.54 | 12 |
Know Syros Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Syros Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Syros Pharmaceuticals backward and forwards among themselves. Syros Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Syros Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs O'connor Llc | 2024-09-30 | 359.3 K | Exoduspoint Capital Management, Lp | 2024-09-30 | 313 K | Walleye Trading Advisors, Llc | 2024-06-30 | 285.8 K | Goldman Sachs Group Inc | 2024-06-30 | 262.4 K | Blackrock Inc | 2024-06-30 | 259.2 K | Omega Fund Management Llc | 2024-09-30 | 251.3 K | Geode Capital Management, Llc | 2024-09-30 | 204.7 K | Marshall Wace Asset Management Ltd | 2024-06-30 | 160.4 K | Exome Asset Management Llc | 2024-06-30 | 159.2 K | Bain Capital Life Sciences Investors, Llc | 2024-09-30 | 2.8 M | Artal Group S A | 2024-06-30 | 2.5 M |
Syros Pharmaceuticals' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.73 M.Market Cap |
|
Syros Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.98) | (1.03) | |
| Return On Capital Employed | (0.98) | (1.03) | |
| Return On Assets | (0.98) | (1.03) | |
| Return On Equity | (9.88) | (9.38) |
Determining Syros Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Syros Pharmaceuticals is a good buy. For example, gross profit margin measures Syros Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Syros Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Syros Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Syros Pharmaceuticals. Check Syros Pharmaceuticals' Beneish M Score to see the likelihood of Syros Pharmaceuticals' management manipulating its earnings.
Evaluate Syros Pharmaceuticals' management efficiency
Syros Pharmaceuticals has return on total asset (ROA) of (0.5988) % which means that it has lost $0.5988 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.7696) %, meaning that it created substantial loss on money invested by shareholders. Syros Pharmaceuticals' management efficiency ratios could be used to measure how well Syros Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.03 in 2024. Return On Capital Employed is likely to drop to -1.03 in 2024. At this time, Syros Pharmaceuticals' Net Tangible Assets are comparatively stable compared to the past year. Debt To Assets is likely to gain to 0.27 in 2024, whereas Total Assets are likely to drop slightly above 147.5 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.59 | 0.56 | |
| Tangible Book Value Per Share | 0.59 | 0.56 | |
| Enterprise Value Over EBITDA | (0.91) | (0.96) | |
| Price Book Value Ratio | 13.24 | 13.91 | |
| Enterprise Value Multiple | (0.91) | (0.96) | |
| Price Fair Value | 13.24 | 13.91 | |
| Enterprise Value | 143.2 M | 99.6 M |
The strategic initiatives led by Syros Pharmaceuticals' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Beta 1.592 |
Basic technical analysis of Syros Stock
As of the 28th of November, Syros Pharmaceuticals has the Coefficient Of Variation of (2,062), variance of 206.68, and Risk Adjusted Performance of (0.03). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Syros Pharmaceuticals, as well as the relationship between them. Please validate Syros Pharmaceuticals risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and kurtosis to decide if Syros Pharmaceuticals is priced more or less accurately, providing market reflects its prevalent price of 0.27 per share. As Syros Pharmaceuticals appears to be a penny stock we also recommend to double-check its jensen alpha numbers.Syros Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Syros Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Syros Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Syros Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Syros Pharmaceuticals' Outstanding Corporate Bonds
Syros Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Syros Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Syros bonds can be classified according to their maturity, which is the date when Syros Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| SYY 315 14 DEC 51 Corp BondUS871829BR76 | View | |
| SYY 245 14 DEC 31 Corp BondUS871829BQ93 | View | |
| US871829BJ50 Corp BondUS871829BJ50 | View | |
| US871829BK24 Corp BondUS871829BK24 | View | |
| SYSCO P 445 Corp BondUS871829BH94 | View | |
| SYSCO PORATION Corp BondUS871829BN62 | View | |
| SYSCO PORATION Corp BondUS871829BL07 | View | |
| US871829BM89 Corp BondUS871829BM89 | View |
Understand Syros Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Syros Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.76) | |||
| Mean Deviation | 7.2 | |||
| Coefficient Of Variation | (2,062) | |||
| Standard Deviation | 14.38 | |||
| Variance | 206.68 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.82) | |||
| Total Risk Alpha | (2.97) | |||
| Treynor Ratio | (0.77) | |||
| Maximum Drawdown | 111.02 | |||
| Value At Risk | (15.48) | |||
| Potential Upside | 19.91 | |||
| Skewness | (2.96) | |||
| Kurtosis | 20.29 |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.76) | |||
| Mean Deviation | 7.2 | |||
| Coefficient Of Variation | (2,062) | |||
| Standard Deviation | 14.38 | |||
| Variance | 206.68 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.82) | |||
| Total Risk Alpha | (2.97) | |||
| Treynor Ratio | (0.77) | |||
| Maximum Drawdown | 111.02 | |||
| Value At Risk | (15.48) | |||
| Potential Upside | 19.91 | |||
| Skewness | (2.96) | |||
| Kurtosis | 20.29 |
Consider Syros Pharmaceuticals' intraday indicators
Syros Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Syros Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Syros Pharmaceuticals time-series forecasting models is one of many Syros Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Syros Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Syros Stock media impact
Far too much social signal, news, headlines, and media speculation about Syros Pharmaceuticals that are available to investors today. That information is available publicly through Syros media outlets and privately through word of mouth or via Syros internal channels. However, regardless of the origin, that massive amount of Syros data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Syros Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Syros Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Syros Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Syros Pharmaceuticals alpha.
Syros Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Syros Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Syros Pharmaceuticals Corporate Management
| James MD | Founder | Profile | |
| Lisa Roberts | Vice Resources | Profile | |
| JD Esq | Chief Development | Profile | |
| Eric Olson | Chief Scientific Officer | Profile | |
| Jason Haas | Chief Officer | Profile |
Additional Tools for Syros Stock Analysis
When running Syros Pharmaceuticals' price analysis, check to measure Syros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syros Pharmaceuticals is operating at the current time. Most of Syros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.